Security key
74365N202
Protagenic Therapeutics, Inc.\new - Common Stock, par value $0.0001 per share (PTIX)
CUSIP: 74365N202
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 159,784
- Total 13F value
- $145,661
- Share change
- +41,626
- SEC-reported price per share
- $0.91
- Number of holders
- 10
- Value change
- +$38,049
- Number of buys
- 5
- Number of sells
- 1
- Shares outstanding
- 869,565
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
10
Top holders
10
PTIX full security history
Ownership snapshot
Full 13F holder table
Protagenic Therapeutics, Inc.\new SEC filings
Protagenic Therapeutics, Inc.\new company facts
Broader feeds
Ownership snapshot
Top reported holders of PTIX - Protagenic Therapeutics, Inc.\new - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
EAGLE ASSET MANAGEMENT INC
Disclosed value leader
EAGLE ASSET MANAGEMENT INC
Comparable rows
0/15
Latest evidence
31 Mar 2024
13F
3/4/5
Highest disclosed value: $11,858,482
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
EAGLE ASSET MANAGEMENT INC has the largest disclosed position value at $11.86M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens EAGLE ASSET MANAGEMENT INC's linked filing trail.
Disclosed position value
Top 5
EAGLE ASSET MANAGEMENT INC
$11.86M
Alexander K. Arrow
$211.1K
Jennifer Buell
$130.5K
Stein Robert Benjamin
$130.5K
Brian Corvese
$76.1K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| EAGLE ASSET MANAGEMENT INC |
13F
Company
|
—
denominator unverified
|
$11,858,482
419,324 shares
|
— | 31 Mar 2024 |
| Alexander K. Arrow |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$211,110
145,815 shares
mixed-class rows
|
— | 25 Mar 2024 |
| Jennifer Buell |
3/4/5
Director
|
—
denominator unverified
|
$130,500
75,000 shares
|
— | 25 Mar 2024 |
| Stein Robert Benjamin |
3/4/5
Director
|
—
denominator unverified
|
$130,500
75,000 shares
|
— | 25 Mar 2024 |
| Brian Corvese |
3/4/5
Director
|
—
denominator unverified
|
$76,125
43,750 shares
|
— | 25 Mar 2024 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$58,041
33,166 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
10
Shares
159,784
Rows available
10
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
10
Q2 2024 holders
10
Holder diff
0
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|